August 29, 2014 6:21 PM ET


Company Overview of Forward Pharma A/S

Company Overview

Forward Pharma A/S, a biopharmaceutical company, focuses on the provision of dimethyl fumarate (DMF) formulations for the treatment of various immune disorders. It develops FP187, a DMF formulation to treat relapsing remitting multiple sclerosis and psoriasis. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.

Ostergade 24A, 1

Copenhagen,  1100


Founded in 2005

10 Employees


45 33 44 42 42


45 33 44 42 44

Key Executives for Forward Pharma A/S

Chief Executive Officer
Age: 62
Co-Founder and Chairman of the Board
Age: 45
Chief Financial Officer
Age: 47
Compensation as of Fiscal Year 2014.

Forward Pharma A/S Key Developments

Forward Pharma A/S Announces Appointment of Jan G. J. Van De Winkel to Board of Directors

Forward Pharma A/S announced that it has appointed Jan van de Winkel, Ph.D, President and Chief Executive Officer of Genmab, to its Board of Directors, effective immediately. Dr. van de Winkel is a co-founder of Genmab and currently serves as President and Chief Executive Officer. He has more than 20 years of experience in the therapeutic antibody field, is the author of over 300 scientific publications and has been responsible for more than 40 patents and pending patent applications. He is chairman of the board of directors of Regenesance and member of the board of directors of ISA Pharmaceuticals and Celdara Medical. Prior to Genmab, Dr. van de Winkel served as Vice President and Scientific Director of Medarex Europe.

Joel Sendek Joins Forward Pharma A/S as Chief Financial Officer

Forward Pharma A/S announced that Joel Sendek has been appointed Chief Financial Officer, effective August 5, 2014. Mr. Sendek will serve as a key member of the executive team providing strategic leadership for the company's financial functions and be responsible for the company's short and long-term financial objectives in support of the business strategy. Mr. Sendek joins the company from Stifel Financial Corp.

Forward Pharma A/S Auditor Raises 'Going Concern' Doubt

Forward Pharma A/S filed its Annual on Aug 11, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
FCMB ApS Europe
Sanos Bioscience A/S Europe
Nanoference ApS Europe
ENKAM Pharmaceuticals A/S Europe
TagAway Devices ApS Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Forward Pharma A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at